2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2001

Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections
Abstract Number: 851

Perioral Autologous FAT Transplantation Is More Effective THAN Hyaluronic Acid Filler on Scleroderma Skin Fibrosis: Results from a LONG TERM Controlled Study
Abstract Number: 2103

Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis
Abstract Number: 366

Peripheral Osteoclastogensis Is Coming Back Along with Inflammation Twelve Months after Rituximab Therapy
Abstract Number: 866

Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?
Abstract Number: 1602

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
Abstract Number: 251

Persistent Pruritic Skin Lesions with Dyskeratotic Cells in Upper Layer of Epidermis Are Specific and Associated with High Levels of Serum IL-18 in Adult-Onset Still’s Disease
Abstract Number: 375

Persistent Tactile Allodynia in Male Arthritic Mice Is Accompanied By Sprouting of Sensory and Sympathetic Nerve Fibers
Abstract Number: 987

Pesticide Exposure and Risk of Rheumatoid Arthritis in Licensed Male Pesticide Applicators in the Agricultural Health Study
Abstract Number: 1285

PET/CT Imaging in Patients with Vascular Behcet Disease
Abstract Number: 2100

Pharmaceutical Disruption of B2GPI CXCL4 Complex Using Computationally Designed Oligopeptides
Abstract Number: 2354

Pharmaceutical Grade Chondroitin Sulfate Improves Knee Osteoarthritis Symptoms More Than Placebo and As Much As Celecoxib: Results of the Chondroitin Vs Celecoxib Vs Placebo Trial (CONCEPT)
Abstract Number: 192

Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
Abstract Number: 196

Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Abstract Number: 197

Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].